For the year ending 2025-12-31, AURX made $3,313,509 in revenue. -$2,512,216 in net income. Net profit margin of -75.82%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 3,313,509 | 1,365,173 | ||
| Costs of sales | 1,095,553 | 302,842 | ||
| Us-gaap_grossprofit | 2,217,956 | 1,062,331 | ||
| Selling, general and administrative | 4,734,605 | 3,520,166 | ||
| Total operating expenses | 4,734,605 | 3,520,166 | ||
| Loss from operations | -2,516,649 | -2,457,835 | ||
| Interest income (expense), net | -804 | 105 | ||
| Gain on settlement of legacy accounts payable obligations | 0 | 133,623 | ||
| Other income | 5,237 | 402 | ||
| Loss before benefit for income taxes | -2,512,216 | -2,323,705 | ||
| Net loss | -2,512,216 | -2,323,705 | ||
| Basic EPS | -0.05 | -0.05 | ||
| Basic Average Shares | 47,312,727 | 45,424,437 | ||
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)